Results: Myriad Genetic's BRCA1/2 gene patents sparked ... Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379–1388.

Maxwell met her at a conference focused on the rare, recessive genetic bone marrow disorder that causes myriad medical challenges ... including BRCA1 or BRCA2. The woman that Maxwell met was ...

Many other genetic variants have been tested, often with conflicting results when evaluated by more than one group or when variants with an apparent effect in carriers of BRCA1/BRCA2 mutations are ...

Genetic mutations like BRCA1 and BRCA2 can increase the risk of breast and ovarian cancer. If you notice cancer in your family, you need to go for early screenings to help catch cancer at ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.

For their analysis, Couch and colleagues collected data from a set of 12 population-based and family-based breast cancer studies in the US, a clinical testing cohort of DCIS and breast cancer patients ...

According to the genetic theory of aging, your genes (as well as mutations ... Many people are familiar with the BRCA1 and BRCA2 mutations which predispose to breast cancer. These genes are referred ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...